The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Subscribe To Our Newsletter & Stay Updated
